Home - Invivoscribe

Cat #: 13080010

BCL1/J_H Translocation Assay for Gel Detection

BACKGROUND This aberrant BCL1/JH t(11;14) translocation juxtaposes genes of the immunoglobulin heavy chain (IGH) gene on chromosome 14q32 with the cyc...

View Product

Cat #: 23080010

BCL1/J_H Tube – Unlabeled for Gel Detection

The aberrant BCL1/JH t(11;14) translocation juxtaposes genes of the immunoglobulin heavy chain (IGH) gene on chromosome 14q32 with the cyclin D1 gene ...

View Product

Cat #: A3090060

BCL2/J_H 3’Mbr – Unlabeled

This product targets the human BCL2/JH fusion gene. ...

View Product

Cat #: A3090050

BCL2/J_H Mbr – Unlabeled

This product targets the human BCL2/JH fusion gene. ...

View Product

Cat #: A3090070

BCL2/J_H mcr – Unlabeled

This product targets the human BCL2/JH fusion gene. ...

View Product

Cat #: 23090020

BCL2/J_H t(14;18) (mcr) Mix 2b – Unlabeled for Gel Detection

BCL2 translocations are reciprocal chromosome exchanges that place the bcl-2 proto-oncogene, located on chromosome 18, under aberrant transcriptional ...

View Product

Cat #: 13090010

BCL2/J_H t(14;18) Translocation Assay for Gel Detection

BACKGROUND BCL2 translocations are reciprocal chromosome exchanges that place the bcl-2 proto-oncogene, located on chromosome 18, under aberrant trans...

View Product

Cat #: 13090020

BCL2/J_H Translocation Assay for Gel Detection

BACKGROUND BCL2 translocations are reciprocal chromosome exchanges that place the bcl-2 proto-oncogene, located on chromosome 18, under aberrant trans...

View Product

Cat #: 23090050

BCL2/J_H Tube A – Unlabeled for Gel Detection

BCL2 translocations are reciprocal chromosome exchanges that place the bcl-2 proto-oncogene, located on chromosome 18, under aberrant transcriptional ...

View Product

Cat #: 23090060

BCL2/J_H Tube B – Unlabeled for Gel Detection

BCL2 translocations are reciprocal chromosome exchanges that place the bcl-2 proto-oncogene, located on chromosome 18, under aberrant transcriptional ...

View Product

Cat #: 23090070

BCL2/J_H Tube C – Unlabeled for Gel Detection

BCL2 translocations are reciprocal chromosome exchanges that place the bcl-2 proto-oncogene, located on chromosome 18, under aberrant transcriptional ...

View Product

Cat #: A3100030

BCR/ABL b2.1-a3.1 – Unlabeled

This product targets the human BCR/ABL fusion gene. ...

View Product

Cat #: 40850310

BCR/ABL b2a2 RNA Dilution Set

Invivoscribe’s BCR/ABL b2a2 RNA Dilution Set consists of RNA that has been extracted from established BCR/ABL b2a2 positive and BCR/ABL negati...

View Product

Cat #: 40850210

BCR/ABL b3a2 RNA Dilution Set

Invivoscribe’s BCR/ABL b3a2 RNA Dilution Set consists of RNA that has been extracted from established BCR/ABL b3a2 positive and BCR/ABL negati...

View Product

Cat #: A3100020

BCR/ABL e1.1-a3.1 – Unlabeled

This product targets the human BCR/ABL fusion gene. ...

View Product

Cat #: 40850110

BCR/ABL e1a2 RNA Dilution Set

Invivoscribe’s BCR/ABL e1a2 RNA Dilution Set consists of RNA that has been extracted from established BCR/ABL e1a2 positive and BCR/ABL negati...

View Product

Cat #: 23100010

BCR/ABL t(9;22) Mix 1a – Unlabeled for Gel Detection

BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...

View Product

Cat #: 23100041

BCR/ABL t(9;22) Mix 1b – HEX for ABI Fluorescence Detection

BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...

View Product

Cat #: 23100020

BCR/ABL t(9;22) Mix 2a – Unlabeled for Gel Detection

BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...

View Product

Cat #: 23100051

BCR/ABL t(9;22) Mix 2b – HEX for ABI Fluorescence Detection

BCR/ABL translocations are associated with a variety of hematologic malignancies. The Philadelphia chromosome (Ph1) is a specific chromosomal abnorm...

View Product

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing